Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Sionna reported a Q2 net loss of $29.9 million, or $0.66 per share, widening from a loss of $18.1 million in the prior year due to higher R&D and administrative costs. The company ended the quarter with $268.3 million in cash and equivalents, which management expects to fund operations into 2028.
Key figures
- Guidance
- PreciSION CF Phase 2a (SION-719) and Phase 1 (SION-451) topline data on track for summer 2026
- Net loss
- 29900000
- Ga expenses
- 10600000
- Rd expenses
- 21900000
- Cash position
- 268300000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.